Scholar Rock’s Post

Scholar Rock has received reports of scammers posting fake jobs using Scholar Rock’s name or making fraudulent job offers in Scholar Rock’s name. We have contacted several job boards to get fraudulent job postings removed. If you see a job that is supposedly advertised by Scholar Rock, please check its validity by visiting our website and applying directly at our careers page, where we’ve also added some tips on how to protect yourself from those scams. Visit: https://lnkd.in/eNqC_PX

Happy #NationalInternDay to our fantastic co-ops and summer interns! We’re lucky to have you at Scholar Rock and appreciate your curiosity, hard work and commitment to #CreatingPossibilities for patients.

Frontiers in Neurology recently published 36-month data from our Phase 2 TOPAZ study. These data further characterize the long-term safety and efficacy profile, and inform our Phase 3 SAPPHIRE trial, which is expected to report topline data in Q4 2024. Read more: https://bit.ly/3Ywr2Ej

Frederick "Chuck" Streich Jr., Senior Principal Scientist at Scholar Rock, will give a short talk and present a poster at the Federation of American Societies for Experimental Biology (FASEB) Science Research Conference characterizing the mechanism of action and clinical potential of our investigational TGFβ1 inhibitory antibodies in development for the treatment of cancer and fibrosis. #TGFSRC 

Scholar Rock is proud to be a Gold Sponsor of the Federation of American Societies for Experimental Biology (FASEB) Science Research Conference on TGFβ signaling. We look forward to presenting a poster next week highlighting the structural characterization and clinical potential of our TGFβ1 inhibitory antibodies. #TGFSRC 

A couple weeks ago, we brought colleagues from across Scholar Rock together to reflect on how their individual roles contribute to advancing our mission of #CreatingPossibilities for patients.    Here's what they had to say: 

Scholar Rock is proud to see recent data on SRK-373, our investigational selective TGFβ inhibitor in development for the treatment of fibrosis, published in Science Signaling, with one of our images featured on the cover of the latest issue.   These data further validate our platform and our approach to selectively targeting TGFβ.    Read more: https://bit.ly/4ctnZAG

Yesterday at #ADA2024, Scholar Rock shared preclinical data from our SRK-439 program in #obesity highlighting the potential of our investigational myostatin inhibitor to promote healthy body composition during GLP-1 receptor agonist-induced weight loss.   Learn more: https://bit.ly/4c8Iz9k

Next week, Scholar Rock will present recent preclinical data from our SRK-439 program in #obesity at the American Diabetes Association 84th Scientific Sessions. #ADA2024